- Company
- Introduction of oral tx for COVID-19
- by Whang, byung-woo Dec 31, 2021 05:50am
- As the U.S. Food and Drug Administration (FDA) has approved the emergency use of Pfizer's Paxlovid, the entry of oral coronavirus treatments into the market is just around the corner. On the 22nd (local time), the FDA approved the use of Paxlovid at home for high-risk adults, children over the age of 12, and patients with underlying diseas
- Company
- Xospata's drug price negotiation period has been extended
- by Eo, Yun-Ho Dec 30, 2021 05:51am
- Drug price negotiations for the new acute myelogenous leukemia drug Xospata, which aims to be exempted, have passed the year. Astellas Korea and the NHIS conducted drug price negotiations until the 20th to register insurance benefits for Acute Myeloid Leukemia (AML), but decided to extend the negotiation deadline without reaching a conclus
- Company
- K-pharma·biopharmas make great tech export deals this year
- by Chon, Seung-Hyun Dec 30, 2021 05:51am
- Once again, Korean pharmaceutical and biopharmaceutical companies have made great technology export performance this year. Although no mega-deals that amount to top 10 licensing deals were made, technology exports were made in various areas in the industry. Also, performance biopharmaceutical companies stood out this year compared to traditi
- Company
- Donepezil Patch, which is about to be released
- by Dec 30, 2021 05:51am
- Celltrion's Donerion Patch, the world's first Donepezil patch, is scheduled to be officially released on the market in the first half of next year. The price of the patch system, which is attached twice a week, is expected to be about 5,000 won per patch. According to the pharmaceutical industry on the 28th, Celltrion Pharmaceutical is c
- Company
- Patents for representative DM drugs are expected to expire
- by Kim, Jin-Gu Dec 29, 2021 05:58am
- Next year, patents for DPP-4 inhibitor-based diabetes treatments such as Tenelia, Onglyza and Galvus will be released one after another. It is predicted that generic companies will join the domestic DPP-4 inhibitor-affiliated diabetes treatment market, which has grown to 600 billion won a year. In the case of generics for Galvus, more than 10
- Company
- A reimbursed optn in hormone-sensitive prostate cancer?
- by Eo, Yun-Ho Dec 29, 2021 05:58am
- Whether a treatment option may be added to the hormone-sensitive metastatic prostate cancer treatment environment that lacked options is gaining attention. According to industry officials, Astellas Korea applied for the extended insurance benefit of its anticancer drug ‘Xtandi (enzalutamide)’ in combination with androgen deprivation the
- Company
- LegoChem transfers candidate technology to British company
- by Chon, Seung-Hyun Dec 29, 2021 05:57am
- LegoChem Biosciences announced on the 27th that it has signed a technology transfer contract with Iksuda for joint development of a new anti-cancer drug candidate LCB14. The contract is worth up to $1 billion (about 1.2 trillion won). With this contract, LegoChem Biosciences secured $50 million (about 60 billion won) in advance payments and shor
- Company
- SK Bioscience will complete major facilities in Songdo
- by Chon, Seung-Hyun Dec 28, 2021 05:51am
- SK Bioscience, the third-largest pharmaceutical bio company in market capitalization, will build a new construction in Songdo, Incheon. It will invest 300 billion won by 2024 to build a new factory and laboratory. Along with Samsung Biologics, Celltrion, and Celltrion Healthcare, the first to fourth place in the pharmaceutical bio market will ga
- Company
- ST Pharm has applied for phase 1 of the COVID-19 vaccine
- by Kim, Jin-Gu Dec 28, 2021 05:50am
- ST Pharm will join the ranks of COVID-19 vaccine development. It introduced mRNA vaccine platforms such as Pfizer and Moderna vaccines. ST Pharm announced on the 24th that it has applied for a phase 1 clinical trial plan for the mRNA-based COVID-19 prevention vaccine STP-2104 to the MFDS. Clinical trials were planned in stages of capaci
- Company
- Ildong's new DM GLP-1 analog has acquired a new patent
- by Dec 28, 2021 05:49am
- Ildong (CEO Yoon Woong-seop) announced on the 24th that it has obtained a patent for domestic substances for ID110521156, a new drug candidate for type 2 diabetes treatment under development. &8203; ID110521156 is a drug in the GLP-1 receptor agonist family that acts as a analog to the Glucagon-like peptide-1 (GLP-1) hormone that regulates
